Syneron Bio said it raised a Series B round worth $150 million, which it will use to back the development of a drug class that’s attracted growing interest because of its potential to borrow some …
European VC Jeito gets $1.2B to help private biotechs control their ‘destiny’
A dozen or so European drug development startups might soon get a major lift from Jeito Capital. The Paris-based firm closed its second fund at



